Published in Sci Rep on February 05, 2016
Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial. J Clin Oncol (2016) 1.00
SOD2 deregulation enhances migration, invasion and has poor prognosis in salivary adenoid cystic carcinoma. Sci Rep (2016) 0.81
miR-139-5p Inhibits the Epithelial-Mesenchymal Transition and Enhances the Chemotherapeutic Sensitivity of Colorectal Cancer Cells by Downregulating BCL2. Sci Rep (2016) 0.78
iASPP induces EMT and cisplatin resistance in human cervical cancer through miR-20a-FBXL5/BTG3 signaling. J Exp Clin Cancer Res (2017) 0.75
Cathepsin L upregulation-induced EMT phenotype is associated with the acquisition of cisplatin or paclitaxel resistance in A549 cells. Acta Pharmacol Sin (2016) 0.75
The Zuo Jin Wan Formula Induces Mitochondrial Apoptosis of Cisplatin-Resistant Gastric Cancer Cells via Cofilin-1. Evid Based Complement Alternat Med (2016) 0.75
Tumor suppressor role of miR-3622b-5p in ERBB2-positive cancer. Oncotarget (2017) 0.75
Pathologic tumor response to neoadjuvant chemotherapy in gastroesophageal cancer: what does it mean? Transl Gastroenterol Hepatol (2016) 0.75
MiR-26b reverses temozolomide resistance via targeting Wee1 in glioma cells. Cell Cycle (2017) 0.75
GNB2L1 and its O-GlcNAcylation regulates metastasis via modulating epithelial-mesenchymal transition in the chemoresistance of gastric cancer. PLoS One (2017) 0.75
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
Epithelial-mesenchymal transitions in development and disease. Cell (2009) 39.17
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
The basics of epithelial-mesenchymal transition. J Clin Invest (2009) 32.82
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 31.55
Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol (2006) 23.04
Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell (2008) 14.80
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol (2002) 13.81
Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol (2014) 10.04
An overview of epithelio-mesenchymal transformation. Acta Anat (Basel) (1995) 9.18
Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer (1999) 8.61
Platinum compounds: a new class of potent antitumour agents. Nature (1969) 5.92
The EGF receptor family as targets for cancer therapy. Oncogene (2000) 5.44
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol (2009) 5.08
NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest (2004) 5.06
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol (2008) 4.63
Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol (2007) 4.12
Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin Cancer Biol (2012) 3.98
Gastric cancer. Lancet (2003) 3.96
Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res (2006) 3.65
Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med (2009) 3.05
Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol (2007) 2.98
The drug resistance-related protein LRP is the human major vault protein. Nat Med (1995) 2.78
Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther (1999) 2.18
Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells. Oncogene (2004) 1.72
Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol (2006) 1.56
Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol (2006) 1.51
Her-2/neu and breast cancer. Diagn Mol Pathol (2001) 1.38
Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance. J Cancer Res Clin Oncol (2009) 1.34
HER2-positive gastric cancer. Gastric Cancer (2013) 1.32
Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer. Br J Cancer (1991) 1.25
ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix. Cancer Res (1994) 1.18
HER 2/neu protein expression in colorectal cancer. BMC Cancer (2006) 1.18
Overexpression of Snail is associated with lymph node metastasis and poor prognosis in patients with gastric cancer. BMC Cancer (2012) 1.16
HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol (1992) 1.11
Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer. Cancer (1993) 1.04
A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients. PLoS One (2011) 1.03
New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives. Future Oncol (2010) 1.02
Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas: a comparative immunohistochemical and fluorescence in situ hybridization study. Mod Pathol (2001) 1.02
Cox-2 and Her2/neu co-expression in invasive bladder cancer. Int J Oncol (2005) 0.98
HER-2/neu oncogene characterization in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg (1995) 0.95
RhoGDI2 confers gastric cancer cells resistance against cisplatin-induced apoptosis by upregulation of Bcl-2 expression. Cancer Lett (2011) 0.94
VEGF-C mediates RhoGDI2-induced gastric cancer cell metastasis and cisplatin resistance. Int J Cancer (2014) 0.94
Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer. ISRN Oncol (2012) 0.92
The expression and significance of P-glycoprotein, lung resistance protein and multidrug resistance-associated protein in gastric cancer. J Exp Clin Cancer Res (2009) 0.90
Mycoplasma hyorhinis infection promotes NF-κB-dependent migration of gastric cancer cells. Cancer Res (2014) 0.88
Epithelial-mesenchymal transition in tumor metastasis: a method to the madness. Future Oncol (2009) 0.86
Anthracycline resistance: the problem and its current definition. Semin Oncol (1997) 0.80
[Establishment of drug resistant cell line of MGC-803 and analysis of differential secretome]. Beijing Da Xue Xue Bao (2014) 0.79
Mycoplasma hyorhinis induces epithelial-mesenchymal transition in gastric cancer cell MGC803 via TLR4-NF-κB signaling. Cancer Lett (2014) 0.79
[Significance of multidrug resistance gene-associated proteins in the postoperative adjuvant chemotherapy for gastric carcinoma and the prognosis]. Zhonghua Wei Chang Wai Ke Za Zhi (2010) 0.78